Page last updated: 2024-12-08

cryptophycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cryptophycin: a potent antitumor cyclic depsipeptide active against drug-resistant cells; from cyanobacteria (blue-green algae) of the genus Nostoc; structure given in first source; [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID381235
MeSH IDM0234039

Synonyms (4)

Synonym
NCI60_023543
cryptophycin
cryptophycin 39
cryptophycin 77

Research Excerpts

Overview

Cryptophycin-1 is a cyanotoxin produced by filamentous cyanobacteria. Cryptophycin is a potent antitumor agent that depletes microtubules in intact cells, including cells with the multidrug resistance phenotype.

ExcerptReferenceRelevance
"Cryptophycin-1 is a cyanotoxin produced by filamentous cyanobacteria. "( Effects of Modification of Light Parameters on the Production of Cryptophycin, Cyanotoxin with Potent Anticancer Activity, in
Dufat, TH; Kirilovsky, D; Michel, S; Polyzois, A, 2020
)
2.24
"Cryptophycins (Crp) are a group of cyanobacterial depsipeptides with activity against drug-resistant tumors. "( Chemoenzymatic synthesis of cryptophycin anticancer agents by an ester bond-forming non-ribosomal peptide synthetase module.
Bolduc, KL; Ding, Y; HÃ¥kansson, K; Rath, CM; Sherman, DH, 2011
)
2.11
"Cryptophycin-38 is a stereoisomer of cryptophycin-1 (1) and to date is the only naturally occurring analogue that possesses a S,S epoxide group in unit A."( Isolation and structure determination of cryptophycins 38, 326, and 327 from the terrestrial cyanobacterium Nostoc sp. GSV 224.
Chaganty, S; Golakoti, T; Heltzel, C; Moore, RE; Yoshida, WY, 2004
)
1.31
"Cryptophycin-309 (C-309) is a glycinate ester of the chlorohydrin Cryptophycin-296."( Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumors.
Aikins, JA; Al-awar, RS; Corbett, TH; Gibson, LL; Hay, DA; Kushner, J; Liang, J; Martinelli, MJ; Moher, ED; Moore, RE; Munroe, JE; Polin, L; Pugh, S; Ray, JE; Shih, C; Simpson, C; Varie, DL; Vasudevan, V; White, K; Zhang, TY, 2005
)
2.49
"Cryptophycin is a cytotoxic dioxadiazacyclohexadecenetetrone isolated from cyanobacteria of the genus Nostoc. "( Cryptophycin: a new antimicrotubule agent active against drug-resistant cells.
Mooberry, SL; Moore, RE; Patterson, GM; Smith, CD; Zhang, X, 1994
)
3.17
"Cryptophycin 1 is an effective inhibitor of tubulin polymerization, causes tubulin to aggregate, and depolymerizes microtubules to linear polymers somewhat similar to the spiral-like structures produced by the Vinca alkaloids."( Interaction of cryptophycin 1 with tubulin and microtubules.
Georg, GI; Himes, RH; Kerksiek, K; Mejillano, MR; Schwartz, RE, 1995
)
1.37
"Cryptophycin is a potent antitumor agent that depletes microtubules in intact cells, including cells with the multidrug resistance phenotype. "( Mechanism of action cryptophycin. Interaction with the Vinca alkaloid domain of tubulin.
Smith, CD; Zhang, X, 1996
)
2.06
"Cryptophycin 1 is a new cytotoxic antimicrotubule agent with excellent antitumor activity. "( Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site.
Busquets, L; Mooberry, SL; Taoka, CR, 1996
)
3.18
"Cryptophycin 1 is a remarkably potent antiproliferative compound that shows excellent antitumor activity against mammary, colon, and pancreatic adenocarcinomas in mouse xenographs. "( Mechanism of action of the unusually potent microtubule inhibitor cryptophycin 1.
Himes, RH; Jordan, MA; Moore, RE; Panda, D; Wilson, L, 1997
)
1.98
"Cryptophycin-52 (LY355703) is a new synthetic member of the cryptophycin family of antimitotic antitumor agents that is currently undergoing clinical evaluation. "( Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends.
DeLuca, K; Jordan, MA; Panda, D; Williams, D; Wilson, L, 1998
)
2.01
"Cryptophycin (CP) is a newly developed anticancer agent isolated from the terrestrial cyanobacteria of the genus Nostoc. "( Cellular uptake of a novel cytotoxic agent, cryptophycin-52, by human THP-1 leukemia cells and H-125 lung tumor cells.
Chen, BD; Nakeff, A; Valeriote, F, 1998
)
2
"Cryptophycin 1 is a natural product that was initially isolated from blue-green algae which has shown potent broad spectrum antitumor activity in preclinical in vitro and in vivo models. "( Cryptophycin 1 cellular levels and effects in vitro using L1210 cells.
Fortuna, M; Foster, BJ; Media, J; Valeriote, FA; Wiegand, RA,
)
3.02
"The cryptophycins are a unique family of 16-membered macrolide antimitotic agents isolated from the cyanobacteria Nostoc sp. "( The cryptophycins: their synthesis and anticancer activity.
Eggen, M; Georg, GI, 2002
)
1.43

Dosage Studied

ExcerptRelevanceReference
" With this strategy, the tumor model is dictated by in vitro cellular sensitivity; drug route by water solubility (with water soluble agents injected intravenously); dosage decrement by drug supply, dose-schedule by toxicities encountered, etc."( Discovery of cryptophycin-1 and BCN-183577: examples of strategies and problems in the detection of antitumor activity in mice.
Corbett, TH; Demchik, L; Golakoti, T; Hetzel, C; Kushner, J; Lowichik, N; Moore, R; Ogino, J; Panchapor, C; Patterson, G; Polin, L; Pugh, S; Rake, J; Valeriote, FA; Wentland, M; White, K, 1997
)
0.67
" Twice-weekly dosing did not allow improvement in dose intensity or tolerability."( Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
Algazy, K; Ellis, D; Enas, N; Gallagher, M; Hahn, S; Johnson, R; O'Dwyer, PJ; Schuchter, L; Stevenson, JP; Sun, W; Thornton, D; Vaughn, D, 2002
)
0.63
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's17 (32.69)18.2507
2000's29 (55.77)29.6817
2010's3 (5.77)24.3611
2020's3 (5.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.34 (24.57)
Research Supply Index4.01 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index38.91 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.89%)5.53%
Reviews4 (7.55%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other48 (90.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]